

# Yu-Tao Guo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1355104/publications.pdf>

Version: 2024-02-01

68  
papers

5,620  
citations

257450

24  
h-index

110387

64  
g-index

74  
all docs

74  
docs citations

74  
times ranked

9721  
citing authors

#	ARTICLE	IF	CITATIONS
1	Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2023, 9, 169-176.	4.0	18
2	Adherence to the "Atrial Fibrillation Better Care"™ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes—A Systematic Review and Meta-Analysis of 285,000 Patients. <i>Thrombosis and Haemostasis</i> , 2022, 122, 406-414.	3.4	219
3	A New Paradigm of "Real-Time" Stroke Risk Prediction and Integrated Care Management in the Digital Health Era: Innovations Using Machine Learning and Artificial Intelligence Approaches. <i>Thrombosis and Haemostasis</i> , 2022, 122, 005-007.	3.4	12
4	Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 191-201.	2.1	7
5	Quality indicators in the management of elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 651-658.	4.0	8
6	Oral anticoagulation improves survival in very elderly Chinese patients with atrial fibrillation: A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>International Journal of Stroke</i> , 2022, 17, 661-668.	5.9	8
7	2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. <i>Thrombosis and Haemostasis</i> , 2022, 122, 020-047.	3.4	192
8	Digoxin use and clinical outcomes in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>Europace</i> , 2022, 24, 1076-1083.	1.7	3
9	4S-CAF scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13751.	3.4	20
10	Mobile health technology in atrial fibrillation. <i>Expert Review of Medical Devices</i> , 2022, 19, 327-340.	2.8	19
11	Outcomes in elderly Chinese patients with atrial fibrillation and coronary artery disease. A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (<scp>ChiOTEAF</scp>) registry. <i>Journal of Arrhythmia</i> , 2022, 38, 580-588.	1.2	2
12	Embolic Stroke of Undetermined Source: The Need for an Integrated and Holistic Approach to Care. <i>Thrombosis and Haemostasis</i> , 2021, 121, 251-254.	3.4	3
13	Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1599-1609.	1.8	93
14	Epidemiology of Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 1-23.	1.7	63
15	Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status. <i>Aging</i> , 2021, 13, 9225-9242.	3.1	15
16	Application of cardiac computed tomographic imaging and fluoroscopy fusion for guiding left atrial appendage occlusion. <i>International Journal of Cardiology</i> , 2021, 331, 289-295.	1.7	12
17	Vital Signs During the COVID-19 Outbreak: A Retrospective Analysis of 19,960 Participants in Wuhan and Four Nearby Capital Cities in China. <i>Global Heart</i> , 2021, 16, 47.	2.3	4
18	Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment. <i>PLoS Medicine</i> , 2021, 18, e1003730.	8.4	8

#	ARTICLE	IF	CITATIONS
19	Beyond atrial fibrillation detection: how digital tools impact the care of patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2021, 93, 117-118.	2.2	3
20	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2021, 37, 1389-1426.	1.2	38
21	Photoplethysmography-Based Machine Learning Approaches for Atrial Fibrillation Prediction. <i>JACC Asia</i> , 2021, 1, 399-408.	1.5	10
22	The Effects of Implementing a Mobile Health Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity. <i>JAMA Network Open</i> , 2021, 4, e2140071.	5.9	27
23	“Real-world” observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). <i>Europace</i> , 2020, 22, 831-832.	1.7	18
24	Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort. <i>European Journal of Internal Medicine</i> , 2020, 82, 105-111.	2.2	94
25	Mobile health technology facilitates population screening and integrated care management in patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 1617-1619.	2.2	10
26	Population-Based Screening or Targeted Screening Based on Initial Clinical Risk Assessment for Atrial Fibrillation: A Report from the Huawei Heart Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1493.	2.4	21
27	Identification of microRNA biomarkers in serum of patients at different stages of atrial fibrillation. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 902-908.	1.6	8
28	Letter by Guo et al Regarding Article, “SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation”. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006635.	2.2	0
29	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	3.4	206
30	The potential for photoplethysmographic (PPG)-based smart devices in atrial fibrillation detection. <i>Expert Review of Medical Devices</i> , 2020, 17, 253-255.	2.8	2
31	Should We Adopt a Standard International Normalized Ratio Range of 2.0 to 3.0 for Asian Patients with Atrial Fibrillation? An Appeal for Evidence-Based Management, Not Eminence-Based Recommendations. <i>Thrombosis and Haemostasis</i> , 2020, 120, 366-368.	3.4	12
32	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1366-1367.	2.8	0
33	Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke. <i>Stroke</i> , 2020, 51, e254-e258.	2.0	213
34	Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1523-1534.	2.8	209
35	Lifestyle and risk factor modification for reduction of atrial fibrillation: We could do more. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 387-388.	4.9	1
36	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	2.8	2,392

#	ARTICLE	IF	CITATIONS
37	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. <i>American Journal of Medicine</i> , 2020, 133, 1195-1202.e2.	1.5	80
38	Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6. <i>Aging</i> , 2020, 12, 19012-19021.	3.1	15
39	Mobile Health for Cardiovascular Disease: The New Frontier for AF Management: Observations from the Huawei Heart Study and mAFA-II Randomised Trial. <i>Arrhythmia and Electrophysiology Review</i> , 2020, 9, 5-7.	2.4	6
40	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 7-8.	1.7	72
41	Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2365-2375.	2.8	294
42	Letter by Guo et al Regarding Article, "Effectiveness of an mHealth-Based Electronic Decision Support System for Integrated Management of Chronic Conditions in Primary Care: The mWellcare Cluster-Randomized Controlled Trial". <i>Circulation</i> , 2019, 139, e1037-e1038.	1.6	1
43	Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF App) II randomised trial. <i>International Journal of Clinical Practice</i> , 2019, 73, e13352.	1.7	56
44	A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian Subjects. <i>Chest</i> , 2019, 155, 510-518.	0.8	124
45	Diagnostic Performance of a Smart Device With Photoplethysmography Technology for Atrial Fibrillation Detection: Pilot Study (Pre-mAFA II Registry). <i>JMIR MHealth and UHealth</i> , 2019, 7, e11437.	3.7	58
46	Validation of Single Centre Pre-Mobile Atrial Fibrillation Apps for Continuous Monitoring of Atrial Fibrillation in a Real-World Setting: Pilot Cohort Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e14909.	4.3	26
47	Risk factors for new-onset atrial fibrillation: A focus on Asian populations. <i>International Journal of Cardiology</i> , 2018, 261, 92-98.	1.7	37
48	Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2018, 131, 185-192.	1.5	49
49	Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study. <i>BMJ Open</i> , 2018, 8, e020191.	1.9	14
50	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. <i>American Journal of Medicine</i> , 2017, 130, 1388-1396.e6.	1.5	172
51	A risk prediction score model for predicting occurrence of post-PCI vasovagal reflex syndrome: a single center study in Chinese population. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 509-514.	0.2	3
52	mHealth For Aging China: Opportunities and Challenges. , 2016, 7, 53.		94
53	Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 184-192.	3.4	26
54	Determinants and Time Trends for Ischaemic and Haemorrhagic Stroke in a Large Chinese Population. <i>PLoS ONE</i> , 2016, 11, e0163171.	2.5	4

#	ARTICLE	IF	CITATIONS
55	Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project. <i>Scientific Reports</i> , 2016, 6, 31755.	3.3	23
56	Long-term outcomes of high-risk elderly male patients with multivessel coronary disease: optimal medical therapy versus revascularization. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 152-7.	0.2	3
57	Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. <i>Chest</i> , 2015, 148, 62-72.	0.8	40
58	Prevalence, Incidence, and Lifetime Risk of Atrial Fibrillation in China. <i>Chest</i> , 2015, 147, 109-119.	0.8	219
59	Effects of Body Mass Index on Risks for Ischemic Stroke, Thromboembolism, and Mortality in Chinese Atrial Fibrillation Patients: A Single-Center Experience. <i>PLoS ONE</i> , 2015, 10, e0123516.	2.5	23
60	Resistin might not be a risk factor for carotid artery atherosclerosis in elderly Chinese males. <i>Journal of Geriatric Cardiology</i> , 2014, 11, 222-8.	0.2	4
61	The Challenge of Antiplatelet Therapy in Patients with Atrial Fibrillation and Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 388-397.	2.4	5
62	Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 904-909.	1.7	67
63	Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 4678-4684.	1.7	52
64	Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 1502-1508.	1.7	25
65	Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: Would the novel oral anticoagulants have an impact?. <i>International Journal of Cardiology</i> , 2013, 168, 515-522.	1.7	35
66	The unmet need of stroke prevention in atrial fibrillation in the far East and South East Asia. <i>The Malaysian Journal of Medical Sciences</i> , 2012, 19, 1-7.	0.5	4
67	Medical treatment and long-term outcome of chronic atrial fibrillation in the aged with chest distress: a retrospective analysis versus sinus rhythm. <i>Clinical Interventions in Aging</i> , 2011, 6, 193.	2.9	3
68	Antithrombotic therapy in very elderly patients with atrial fibrillation: Is it enough to assess thromboembolic risk?. <i>Clinical Interventions in Aging</i> , 2010, 5, 157.	2.9	15